Trial Profile
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes; Keratoconjunctivitis sicca
- Focus Registrational; Therapeutic Use
- Acronyms Emerald
- Sponsors Ocular Technologies; Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 14 Oct 2019 Results published in the Sun Pharmaceutical Industries Media Release
- 16 Aug 2018 According to a Sun Pharmaceutical media release, the US FDA has approved OTX-101 (cyclosporine A, ophthalmic solution) 0.09% to treat dry eye disease.
- 27 Dec 2017 According to a Sun Pharmaceutical media release, the US FDA has accepted a New Drug Application (NDA) for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%.